EHR alert tool effectively screens for sleep apnea in epilepsy patients

An electronic health record (EHR) alert was able to effectively screen for obstructive sleep apnea (OSA) in epilepsy patients and refer them for sleep studies to better diagnose their disorders.

Researchers at Rutgers University in New Brunswick, New Jersey, developed, implemented and evaluated the EHR alert tool in an effort to prove its effectiveness in screening for OSA in patients with epilepsy, according to a study published in Neurology Clinical Practice.

According to the study, previous research has shown that people with epilepsy have a higher prevalence of OSA, which contributes to poor seizure control, and the detection and treatment of OSA can improve seizure control in some patients with epilepsy.

Researchers developed an assessment for identifying OSA and embedded that into an EHR. If a patient had two risk factors, they were then referred for a sleep study.

Prior to the EHR alert being implemented, only 7.23 percent of patients with epilepsy were referred for a sleep study, according to the study. Of those referred, 56 percent were diagnosed with sleep apnea. After the alert was implemented, about 33.1 percent were referred for sleep studies. Of the people who completed a sleep study, 87 percent had at least mild sleep apnea.

“It was found that placing this mandatory alert for providers to screen for OSA in the EHR markedly increased the detection of at-risk epilepsy patients who should be referred for a sleep study,” Rutgers professor and study co-author Xue Ming said in a statement. “Such screening can lead to early detection and treatment, which will improve the quality of life of patients with epilepsy and OSA.”

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.